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Abstract
Primary breast lymphoma (PBL) is a rare disease accounting for 0.4-0.5% of all
breast malignancies. Diffuse large B-cell lymphoma (DLBCL) is the most common
histological diagnosis. The clinical presentation of PBLs is usually no different
from that of carcinoma. In this paper we review the literature on the clinical
presentation, diagnosis, prognostic factors and treatment options of PBL. In the
light of the information gained we discuss three patients with primary breast
lymphoma (one with a central nervous system relapse) who were treated in our
department in the years 2002-2007. In conclusion: there is no consensus on the
question of how to best treat PBL: chemotherapy, radiotherapy or combined
therapy. However, the last approach to be the most successful one. Due to high
incidence of central nervous system (CNS) involvement in PBL patients, many
authors strongly believe that patients with aggressive forms of PBL should
receive CNS infiltration prophylaxis, even in the early stages, as this may improve
the outcome and significantly reduce the risk of a CNS disease relapse.
K Ke ey y   w wo or rd ds s: :   primary breast lymphoma, diffuse large B cell lymphoma, extranodal
non-Hodgkin lymphoma.
Introduction
The  term  “primary  breast  lymphoma”  (PBL)  is  used  to  define
a malignant lymphoma primarily occurring in the breast in the absence of
previously detected lymphoma localizations [1]. PBL is a rare disease,
accounting for only 0.4-0.5% of all breast malignancies, 0.38-0.7% of all
non-Hodgkin lymphomas (NHL), and 1.7-2.2% of extranodal NHL. The
median age of patients with diagnosed PBL ranges from 60 to 65 years
[1-12]. The disease occurs almost exclusively in women. Bilateral breast
involvement accounts for 11% of all breast lymphomas [13] or 5% according
to Ryan et al. [11]. This rare situation is especially observed during
pregnancy or postpartum, suggesting that tumour growth is influenced
by hormonal stimulation. 
Breast lymphoid cells probably originate in mucosa-associated lymphoid
tissue (MALT) [14]. PBL may also originate from lymphatic tissue present
within the breast adjacent to ducts and lobules, or from intramammary
lymph nodes [15, 16]. 
More than 80% of PBL are B-cell lymphomas, mostly CD20+. The most
frequent histopathologic types are: diffuse large B-cell lymphoma (DLBCL)
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which accounts for up to 50% of all PBL, follicular
lymphoma (FL) – 15%, MALT lymphoma – 12.2%,
Burkitt’s lymphoma (BL) and Burkitt-like lymphoma
– 10.3% [17]. Other histological types of PBL include
marginal zone lymphoma (MZL), small lymphocytic
lymphoma  (SLL),  and  anaplastic  large  cell
lymphoma (ALCL).
Diffuse large B-cell lymphoma (DLBCL) is the
most common histological diagnosis. These lym  -
phomas have been shown to be of a non-germinal
centre B-cell phenotype with a high proliferation
index and are thought to be associated with a poor
outcome [18]. There is a close association between
ALCL and silicone breast implants [19, 20]. 
Burkitt’s lymphoma is observed particularly in
pregnant or lactating women and HIV-seropositive
patients. The clinical presentation of PBL and the
radiological features are usually no different from
those of carcinoma of the breast. PBL is usually
classified  according  to  the  Ann  Arbor  staging
system. Other diagnostic criteria for PBL were
described  by  Wiseman  and  Liao  in  1972  [21].
According to the last classification, the clinical site
of presentation is the breast. A history of previous
lymphoma or evidence of widespread disease are
absent  at  diagnosis.  There  is  present  close
association of lymphoma to breast tissue in the
pathologic specimen. Ipsilateral lymph nodes may
be involved. This definition of PBL comprises only
tumours being in stage I (lymphoma limited to the
breast) and stage II (lymphoma limited to the
breast  and  axillary  lymph  nodes)  and  not  to
tumours originating from non-breast sites. Here we
present 3 cases of patients with PBL (2 with DLBCL
and 1 with FL) treated in the years 2002-2007.
Epidemiology and clinical manifestation
A painless mass is the most common presenting
sign in PBL occurring in approximately 61% of cases,
especially (48%) in the external superior quadrant.
Other symptoms and signs are the following: local
pain – 12%, local inflammation – 11%, palpable
lymph nodes – 25%, incidental mammography
finding – 12% [1]. Mammographic findings are
nonspecific. Most of the lesions are oval-shaped
(71%)  and  high-density  (90.9%)  masses.  The
masses revealed by ultrasound examination are
single (75%), circumscribed (50%), microlobulated
(37.5%) and oval (50%). The echo pattern of the
mass is usually hypoechoic (87%). No masses have
spiculated margins or calcifications [22]. Fine needle
aspiration, core biopsy and excisional biopsy are
effective techniques used in the evaluation of
breast nodules and axillary lymph nodes. However,
histological, immunohistochemical and, sometimes,
genetic studies are necessary for establishing the
diagnosis. 
Prognostic factors
There are many controversies about prognostic
factors for patients with PBL. One of these is the
histological subtype of PBL. According to Ryan et
al. [11], a favourable International Prognostic Index
(IPI) score, the use of anthracycline-containing
chemotherapy, and radiotherapy (RT) are signi  -
ficantly associated with longer overall survival (OS).
Similarly, Jeanneret-Sozzi [1] confirmed, by means
of univariate analysis, that favourable prognostic
factors are: early stage (IE), conservative surgery,
RT  administration  and  combined  modality
treatment. Multivariate analyses also confirm that
the  early  stage  and  use  of  RT  are  favourable
prognostic factors. According to Lin et al. [23], the
Ann Arbor stage, the IPI excluding stage, lactic
dehydrogenase  (LDH)  and  radiotherapy  are
significant factors for relapse-free survival. Ganjoo
et al. [13], in their analysis of 37 patients with PBL
– DLBCL, found that elevated LDH and an Eastern
Cooperative Oncology Group (ECOG) performance
status of more than 2 adversely correlated with OS.
There are also studies where the authors suggest
age to be an independent predictor of outcome [8,
24]. Jennings et al. [17] in a Cox regression model,
analyzing the tumour size and node status, revealed
that the node status is the best single predictor of
survival. Contrary to many studies, Aviles et al. [3],
in univariate analysis, did not show that any of the
following prognostic factors influenced response:
event-free survival (EFS), OS: age, tumour size, IPI
score or Ann Arbor stage.
Therapeutic options and clinical outcome –
review of articles 
Ganjoo  et  al. [13]  searched  the  Stanford
lymphoma database for patients with documented
lymphoma involving the breast between 1981 and
2005 and included 37 patients in their analysis.
Diagnostic tissue biopsies were obtained, either
from the breast mass or from an involved lymph
node. DLBCL was the most common histological
subtype, being diagnosed in 49% of their patients;
in turn FL and MZL was diagnosed in 38%. Most
patients presented with a painless, unilateral breast
mass in stage I(E) or II(E), while only one patient
had CNS disease. Their DLBCL patients received
doxorubicin-based  chemotherapy,  with  70%
receiving involved-field radiotherapy (IFRT) with
doses  of  3600-5040  cGy.  A single  patient
additionally received cytotoxic intrathecal therapy.
No recurrences occurred in the involved breast.
A single parenchymal CNS recurrence was recorded.
Among the DLBCL patients, 5-year progression-free
survival (PFS) was 61%, with a median follow-up of
3.8 years (range: 5 months to 19 years) and a 5-year
OS was estimated at 82%. Patients with indolentArch Med Sci 1, February / 2011 29
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lymphoma had an estimated 5-year PFS of 76% and
an OS of 92%. The authors conclude that DLBCL of
the  breast  can  be  successfully  treated  with
doxorubicin-based chemotherapy alone or with IFRT.
In 2008, Ryan et al. [11] published the results of
a retrospective international study of 204 eligible
patients  with  PBL  DLBCL  histological  subtype
attending the International Extranodal Lymphoma
Study Group-affiliated institutions from 1980 to
2003. The median age was 64 years, median OS
was 8.0 years, and median progression-free survival
(PFS) was 5.5 years. There was no benefit from
mastectomy, as opposed to biopsy or lumpectomy.
At a median follow-up time of 5.5 years, in 35% of
patients the tumour had progressed: 16% locally in
the same or contralateral breast, 5% in the CNS and
14% in other extranodal sites. According to the
authors,  the  combination  of  limited  surgery,
anthracycline-containing  chemotherapy,  and
involved-field RT produced the best outcome in the
pre-rituximab era. In conclusion, they postulated
that a combined therapy was the best method of
treating patients with PBL. They suggested using
prophylaxis  to  avoid  central  nervous  system
involvement.
A similar opinion was expressed by Aviles et al.
[3] on the basis of their prospective study. 96
patients in the early stage (I or II according to the
Ann Arbor criteria) of PBL, most of them within an
intermediate IPI score risk, were included. They
were enrolled to receive IFRT with a total dose of
45 Gy, chemotherapy (6 ￗ CHOP-21), or combined
therapy (6 cycles of CHOP and radiotherapy with
a total dose of 30 Gy). Surgery was not considered
as initial therapy. Those patients who failed to
respond to radiotherapy received a chemotherapy
regimen. In patients who failed to respond to
chemotherapy,  radiotherapy  was  employed  at
a dose of 45 Gy. If the failure was outside the
breast, they were treated with salvage regimens. 
Complete remission was confirmed in 20 of the
30 patients treated with radiotherapy, in 19 of the
32 who were treated with chemotherapy and in 
30 of the 34 in the combined arm (p < 0.01). At
a medium follow-up of 10 years’ event-free survival
(EFS)  was  50%,  57%  and  83%,  respectively 
(p < 0.01). Overall survival at 10 years was 50%, 
50% and 76% (p < 0.01), respectively. Treatment-
related acute toxicity was mild, and no second
neoplasm or acute leukaemia was observed.
The most common site of relapse of PBL was the
CNS. Such relapses were treated with high-dose
methotrexate (HD MTX) 6 g/m2 administered every
28 days for at least four cycles. Patients who had
a relapse  outside  the  CNS  were  treated  with
intensive chemotherapy, including ASCT. A second
response was observed in 6 of 11 patients with
relapse in the CNS, and 8 of 12 patients with
another site of relapse. All the patients with relapse
in the CNS died due to progressive disease. In
another study, Aviles et al. [25] evaluated the impact
of a rituximab’s (monoclonal antibody against
CD20) addition and dose density chemotherapy
regimen on the clinical outcome as measured by
EFS and OS. In this single arm prospective study,
patients with early stage DLBCL-PBL were allocated
to  receive  6  cycles  of  chemotherapy  CEOP-R
(cyclophosphamide  1500  mg/m2 i.v.  on  day  1,
epirubicin 120 mg/m2 i.v. on day 1, vincristine 
1.2 mg/m2 i.v. on day 1, prednisone 100 mg/m2 p.o.
daily, on day 1-5, rituximab 375 mg/m2 i.v. on day 1)
administered every 14 days. Granulocyte colony-
stimulating factor (G-CSF) 5µg/kg/day was started
on the second day. There were no differences in
either the CR (87%) or EFS (63%) rates, compared
to the patients described in their previous study.
Gholam et al. [26] analyzed 34 cases of PBL over
a 25-year period. 20 patients were treated with
CHOP or a CHOP-like chemotherapy regimen. All
these 20 PBL cases were of B-cell origin (including
one case of Burkitt’s lymphoma and 2 cases of low-
grade histological type). Sixteen of the 20 patients
achieved CR and 2 achieved a partial remission (PR)
(> 75% tumour regression). The remaining two
patients had progressive disease during therapy.
Within a median follow-up period of 80 months, 
6 patients relapsed. Median time from diagnosis to
relapse was 23 months (range: 3 to 41 months). Two
of the relapses involved the CNS. The neoplasm 
of two patients who achieved a PR after che  -
motherapy spread to the CNS. All 4 patients with
CNS involvement died. Three of the patients in this
study  (15%)  developed  a contralateral  breast
relapse. At the time of writing, 12 of the initial 20
patients were alive, including 11 with a persistent
CR, 6 patients had died of their lymphomas and 
2 of unrelated diseases. In conclusion, they observed
a high incidence of CNS relapse in this group of
localized  extranodal  lymphoma.  This  strongly
suggests that CNS prophylaxis should be associated
with systemic chemotherapy in localized PBL.
Jeanneret-Sozzi et al. [1] analyzed the clinical
profile, treatment, outcome and prognostic factors
of  84  patients  with  PBL,  hospitalized  in  the
institutions of the Rare Cancer Network between
1970 and 2000. 21 of the patients underwent
a mastectomy, 39 conservative surgery and 23
biopsy.  The  majority  of  patients  received
postoperative treatment: 37 radiotherapy combined
with  chemotherapy,  22  chemotherapy  only, 
14 radiotherapy only, whereas 11 patients had no
treatment after surgery. The median RT dose was
40 Gy (range 12-55 Gy). Fifty nine of the 84 patients
(70%)  were  treated  with  chemotherapy  (the
majority  with  CHOP  or  CHOP-like  regimens).
Following  this  treatment,  12%  of  patients30 Arch Med Sci 1, February / 2011
experienced a local relapse, while a systemic relapse
was observed in 55% of the patients. CNS was the
site of relapse in 14% of the patients. Out of the 
12 patients with CNS relapse, 85% had a high grade
lymphoma. The median time to systemic relapse
was 22 months (range: 4 to 140). The 5-year OS,
lymphoma-specific survival, disease-free survival
and local control rates were 53%, 59%, 41%, and
87%, respectively. The authors conclude that the
outcome of PBL is only fair. Local control is excellent
with RT or combined modality treatment, but
systemic relapses, including those in the CNS, occur
frequently.
Jennings et al. [17] published a meta-analysis of
465 PBL cases from 3 decades (1972-2005). Follow-
up ranged from one to 288 months (mean 48
months). The age range was 17 to 95 years (mean
54 years). DLBCL was the most common histological
diagnosis (53%). The patients were included and
classified  according  to  the  Wiseman  and  Liao
definition [19]. This study found that mastectomy
offered no benefit, either in the treatment of PBL
or in protection from recurrence. Treatment that
included radiation therapy in stage I patients (node
negative)  showed  benefit  in  both  survival 
(p = 0.002) and recurrence rates. Treatment that
included chemotherapy in stage II patients (node
positive) showed benefits in both survival and
recurrence rates. Data regarding combined radiation
and chemotherapy were equivocal, due to small
sample sizes but, together, they probably had the
same survival and recurrence advantages as single
treatment  options  in  appropriate  node  status
groups. The authors emphasized the importance of
node status for patients with PBL.
In table I we present review of the literature.
Case 1
A 70-year-old  woman  underwent  cholecys  -
tectomy in 2002 and a partial gastrectomy due to
peptic  ulcer  in  2003.  Physical  examination  in
February 2005 revealed a tumour in the upper-
external  quadrant  of  her  left  breast.  Detailed
physical examination and ultrasonography (USG)
revealed axillary lymphadenopathy. Surgery was
performed and the tumour and the axillary lymph
nodes  were  removed.  Histopathological  and
immunohistochemical findings in the tumour mass
and  lymph  nodes  confirmed  the  diagnosis  of
a diffuse large B-cell type primary breast lymphoma:
CD20+, CD3–, cytokeratin negative. Paraffin-section
studies  were  positive  for  Ki  67  in  80%  of
neoplasmatic cells. There were no abnormalities in
computerized tomography (CT) of the thorax and
abdomen. The patient was treated with 6 cycles of 
CHOP (cyclophosphamide 750 mg/m2 i.v. on day 1,
doxorubicin 50 mg/m2 i.v. on day 1, vincristine 2 mg
i.v. on day 1, prednisone 100 mg p.o. daily, day 1-5)
from March to July 2005. Examination in September
2005 indicated complete remission (CR). However
in May 2007, she started to complain of weakness,
fever,  and  sweating.  On  physical  examination
a palpable lymph node of 2 cm in diameter was
detected in the right axillary tail, and others in the
thorax near the aorta, in the upper part of the
abdomen and in the liver niche. Additionally, some
fluid in the left pleural cavity and pathological
changes  in  the  spleen  were  found.  The  bone
marrow  histopathology  showed  that  (thinly
distributed) lymphocytes accounted for 50% of cells.
CHOP polychemotherapy combined with rituximab
(375 mg/m2) was started. Due to cardiological
complications, a decision was taken to withdraw
the anthracyclines from the second and third cycles
of chemotherapy. After three cycles, no peripheral
lymphadenopathy, no pleural fluid, and no changes
in the spleen were found. Additionally, a reduction
in the size of lymph nodes in the thorax was
observed. Due to anaemia and thrombocytopenia,
erythrocyte and platelet transfusions were given.
After a total of six cycles of chemotherapy the
physical  examination  did  not  reveal  any
abnormalities. The CT of the thorax and abdomen
was normal. There were no signs in the bone
marrow smear and trephine biopsy of infiltration
by lymphoma. A second CR was confirmed and 15
months later still persists.
Case 2
A 55-year-old  patient  had  undergone  thy  -
roidectomy and radioiodine therapy due to goiter
in 1987. In May 2006, she complained of pain in the
left breast which had been present for a few years,
but no irregularity was detected during palpation.
However, in November 2006 palpation did reveal
a mass in the left breast. The patient underwent
tylectomy. Macroscopically there were two lymph
nodes of 3 ￗ 2.3 cm and 3 ￗ 1.5 cm together 
with some fat tissue. Histological and immuno  -
histochemical  studies  revealed  the  following:
a follicular lymphoma (grade 2/3, predominantly
follicular) with bcl2+, CD20+, CD3–, CD43–, CD23–,
CD10+, CD5–. There were no abnormalities in the
computerized  tomography  of  the  thorax  and
abdomen. There was, however, a palpable lymph
node of 0.6 cm in diameter in the right axillary tail.
Bone marrow morphological analysis and flow
cytometry  analysis  did  not  reveal  lymphoma
infiltration. Moreover, a trephine biopsy did not
reveal any neoplastic cells in the bone marrow. The
patient  was  therefore  diagnosed  with  stage  I
A lymphoma according to the Ann Arbor classi  -
fication and CHOP chemotherapy was introduced.
Due to the limited stage of the disease, only three
cycles of the chemotherapy were given. There were
no complications during the treatment. Mammo  -
Monika Joks, Krzysztof Myśliwiec, Krzysztof LewandowskiArch Med Sci 1, February / 2011 31
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graphy and CT of thorax and abdomen confirmed
CR. During an 18 month follow-up period no relapse
was observed.
Case 3
A 58-year-old  woman  was  admitted  to  our
hospital in May 2007 with a clinical diagnosis of
lymphoma relapse in her CNS. In 2002, a mass in
the external-superior quadrant of the left breast
had been detected. Core needle biopsy confirmed
the presence of diffuse large B cell lymphoma
according to WHO. Paraffin-section studies were
positive for CD20, Bcl2, and MIB 1, but negative for
CD3. Bone marrow examination and CT of the
thorax  and  abdomen  did  not  reveal  any
abnormalities.  She  received  6  cycles  of  CHOP
chemotherapy. In restaging CR was confirmed, but
in May 2007 she complained of headache and
confusion.  In  magnetic  resonance  (MR)  two
tumours were revealed in the CNS. One of them,
located in the left occipital lobe, was 17 ￗ 20 
ￗ 15 mm in diameter. The second one (37 ￗ 36 
ￗ3 7mm in diameter) was revealed in the left
temporal lobe. Radiotherapy of the CNS (40 Gy) was
performed.  Staging  procedures,  consisting  of 
a bone marrow examination, CT of the thorax and
abdomen were performed and did not reveal any
other sites of relapse. MR of her head showed
reduction  in  the  tumour’s  mass  by  75%.  We
instituted multi-drug chemotherapy with HD MTX
and high-dose of arabinoside cytosine (HD AraC)
and,  after  3  cycles  MR  revealed  a further
improvement: occipital tumour had disappeared,
while the tumour in the temporal lobe had shrunk
to 12 ￗ 10 ￗ 8 mm in diameter. The patient was
qualified for autologous stem cell transplantation
(ASCT)  but  unfortunately,  mobilization  of
hematopoietic stem cells failed twice. No symptoms
of disease relapse were observed after a follow-up
period of 8 months.
In table II we present summary of three cases.
Discussion 
The behaviour of primary lymphoma of the
breast  is  thought  to  be  similar  to  that  of
lymphomas of the same histological types and
stages arising at other sites. The patients with PBL
probably  also  have  a stage-for-stage  clinical
outcome. The method chosen for treating PBL using
radiation therapy and/or chemotherapy also varies
in the literature. Currently, the use of combined
therapy is considered to be more useful treatment
of patients with PBL even in the early stages of their
illness  [15,  21,  27,  28].  Mastectomy  is  not
recommended because it offers no benefit as
regards  survival  or  recurrence  risk.  The  most
common chemotherapy agents used in PBL have
been those in the CHOP regimen. Strategies to
minimize the cardiac toxicity risks associated with
doxorubicin-containing combination regimens, by
using  adjuvant  radiation  therapy,  have  been
reported for non-Hodgkin’s lymphoma of sites other
than breast and may be important [29].
Rituximab has been registered for treatment of
DLBCL and FL. To our knowledge, there are no
valuable data that confirm improvement after the
addition of rituximab in patients with DLBCL- and
FL-PBL. The efficacy of rituximab is well documented
in  other  CD20+  B  cell  lymphomas.  Therefore,
prospective trials should be pursued to check the
impact of using rituximab on clinical outcome and
patterns of relapse. However, it will be difficult due
to low incidence of PBL in the general population.
Most authors recommend that aggressive forms
of  PBL  should  have  CNS  prophylaxis  even  in 
the early stages. In our opinion, in some forms of
PBL  (i.e.  with  CNS  involvement)  combination
chemotherapy including HD MTX and/or HD Ara-C
may improve the outcome and significantly reduce
the future risk of CNS relapse. The latest suggestion
may be supported by follow-up of our patient with
CNS relapse of PBL. 
S Se ex x/ /a ag ge e H Hi is st to op pa at th ho ol lo og gi ic ca al l   d di ia ag gn no os si is s T Tr re ea at tm me en nt t R Re es su ul lt ts s
F/70 DLBCL  6 ￗ CHOP  CR, relapse
(CD20+, CD3–, cytokeratin negative, Ki67 80%) 6 ￗ CHOP-R CR
F/55 FL (grade2/3)  3 ￗ CHOP CR
(bcl2+, CD20+, CD3–, CD43–, CD23–, CD10+, CD5–)
F/58 DLBCL  6 ￗ CHOP-CR PR
(CD20+, Bcl2+, MIB 1+, CD3–) CNS relapse – 
radiotherapy (40 Gy) 
and chemotherapy 
(3 ￗ HD MTX/HD Ara C) PR
HSC mobilization Ineffective
F – female, DLBCL – diffuse large B-cell lymphoma, FL – follicular lymphoma, CR – complete remission, PR – partial remission, CNS – central
nervous system, HD – high doses, HSC – hematopoietic stem cells
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